MediciNova’s MN-001 meets primary end point in NASH / NAFLD study

This article was originally published here

MediciNova said its MN-001 (tipelukast) has met its primary endpoint of reducing mean serum triglycerides in the phase 2 clinical trial of non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) with hypertriglyceridemia.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply